Yatong Li
Sixty Degree Capital
PrincipalDr. MAHMOOD MAHMOOD
NPI is headquartered in Toronto, Ontario, Canada and will globally distribute and commercialize its AABH based diagnostic tests. NPI’s diagnostic tests are regarded as revolutionary as they can help to diagnose cancer at an early stage using a blood serum with high sensitivity/high specificity, fast turnaround (within 7 hours), are relatively inexpensive and are non-invasive.
Next Pharma Inc.
Aspartyl (Asparaginyl) β Hydroxylase (AABH), Cancer Biomarker, Companion Imaging, and Diagnostic StrategyMr. Richard McCrae
Kymeris therapeutics Inc
President & CEODr. Doreen Miao
Ananda Devices is a biotech company specialized in in vitro assay developments. Leveraging our proprietary nano-organization technology, we have developed physiologically relevant in vitro models that generate predicative responses early on in the compound development processes, thereby accelerating compound discovery and de-risking key developmental investments.
Our nervous on-a-chip technology enables clients to perform drug screening, toxicity and efficacy testing up to 50x faster and 90% more cost-effective. We have 20+ years of experience in neuroscience and tissue engineering, and we have been a developer of unique devices to grow brain, spinal cord and innervated skin models for clients in 12 countries.
Our product:
NeuroHTSTM is a first-in-class high throughput screening (HTS) platform to rapidly cultivate over 3,000 CNS or PNS neurons/plate into physiologically relevant networks.
Its easy-to-use technology requires no additional equipment such as shakers and tubing.
It is compatible with most automation solutions, suitable for both and human/animal models
Our customized services:
Our core technology enables 4 types of innovative assay developments:
-Organization of cell and tissue types for reproducible and physiologically relevant in vitro testing
-Innervation of different tissues
-Miniaturization of existing models to increase throughput and sensitivity
-Development of complex co-culture models to mimic disease on-a-chip
Ananda Devices
Business DirectorDr. Anton Neschadim
ImmunoBiochem’s IMB-213I candidate delivers a potent innate immune system agonist for the treatment of highly heterogeneous solid tumors, such as TNBC, pancreatic and ovarian cancers.
ImmunoBiochem's IMB-212 candidate delivers a potent cytotoxic payload into difficult-to-treat solid tumors, particularly where no suitable surface targets and no biologics are available.
ImmunoBiochem
CEOMariusz Olejniczak
Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.
With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.
WPD Pharmaceuticals
CEOMr. Leo Petrilli
Virtual meetings Host, Guest, Panelist, Master of Ceremonies.